{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:24:18Z","timestamp":1793831058661,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.critrevonc.2023.103984","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:35:18Z","timestamp":1680716118000},"page":"103984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Real-world experience with CPX-351 in high-risk acute myeloid leukemia"],"prefix":"10.1016","volume":"185","author":[{"given":"Roberto M.","family":"Lemoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-142990","article-title":"CPX351 has short remission duration but is an effective bridge to allogeneic transplant in high risk AML: results from Canadian real-world multi-centre study","volume":"136","author":"Andrews","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103984_bib2","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103984_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103984_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103984_bib5","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1080\/10428194.2021.1907378","article-title":"Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia","volume":"62","author":"Benitez","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2023.103984_bib6","series-title":"Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the Spanish PETHEMA registry","author":"Bernal","year":"2022"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103984_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia","volume":"36","author":"Chen","year":"2019","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103984_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103984_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103984_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers14051278","article-title":"Measurable residual disease in high-risk acute myeloid Leukemia","volume":"14","author":"Cluzeau","year":"2022","journal-title":"Cancers"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib11","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.clml.2019.07.084","article-title":"Pooled clinical safety analysis of CPX-351 versus conventional chemotherapy in patients with newly diagnosed or relapsed\/refractory acute myeloid leukemia","volume":"19","author":"Cortes","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103984_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103984_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103984_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103984_bib15","unstructured":"European Medicines Agency, 2018. Vyxeos liposomal 44 mg\/100 mg powder for concentrate for solution for infusion. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyxeos-liposomal\u3009. (Accessed October 31 2022)."},{"key":"10.1016\/j.critrevonc.2023.103984_bib16","unstructured":"Fianchi, L., Guolo, F., Marchesi, F., Cattaneo, C., Gottardi, M., Restuccia, F., Candoni, A., La Barbera, E.O., Pasciolla, C., Finizio, O., Fracchiolla, N., Delia, M., Lessi, F., Michela Dargenio, M., Bonuomo, V., Del Principe, M.I., Zappasodi, P., Picardi, M., Basilico, C., Piedimonte, M., Ospedalieri, P., Criscuolo, M., Dragonetti, G., Giammarco, S., Prezioso, L., Buquicchio, C., Melillo, L., Zama, D., Busca, A., Pagano, L., 2021. Multicenter Observational Retrospective Study on Bacterial\/Fungal\/Viral Infections in Patients with Secondary Acute Myeloid Leukemia Treated with CPX-351 in 'Real-life'. Poster EP491 presented at European Hematology Association (EHA) Annual Congress; Virtual, June 9\u201317 2021."},{"key":"#cr-split#-10.1016\/j.critrevonc.2023.103984_bib17.1","unstructured":"Garibaldi, B., Brunetti, L., Mauro, E., Maugeri, C., Parisi, M.S., Fiumara, P.F., Duminuco, A., Palumbo, G.A., Di Raimondo, F., Vetro, C., 2022. CPX-351 in therapy related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a multicenter real-life experience in young patients (<60 years old). Poster P535 presented at European Hematology Association (EHA) Annual Congress"},{"key":"#cr-split#-10.1016\/j.critrevonc.2023.103984_bib17.2","unstructured":"Vienna, Austria, June 9-12 2022."},{"key":"10.1016\/j.critrevonc.2023.103984_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.12.002","article-title":"CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation","volume":"53","author":"Gordon","year":"2017","journal-title":"Leuk. Res."},{"issue":"31","key":"10.1016\/j.critrevonc.2023.103984_bib19","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2021-145947","article-title":"Comparing outcomes between liposomal daunorubicin\/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia","volume":"138","author":"Grenet","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103984_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103984_bib22","first-page":"96","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood","volume":"10","author":"Guolo","year":"2020","journal-title":"Cancer J."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib23","first-page":"3443","article-title":"Prognostic impact of minimal residual disease assessment in elderly patients with secondary acute myeloid leukemia. a comparison between CPX-351 and intensified fludarabine-based regimens","volume":"138","author":"Guolo","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103984_bib24","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2010-10-265603","article-title":"Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns","volume":"117","author":"Gupta","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103984_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103984_bib26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103984_bib27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103984_bib28","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1080\/10428194.2021.1919668","article-title":"Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)","volume":"62","author":"Jacoby","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood-2021-149700","article-title":"Outcomes of patients treated with CPX-351 as first line therapy for AML based on their antecedent history of myeloid malignancy","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103984_bib30","unstructured":"Jazz Pharmaceuticals Inc., 2022. VYXEOS\u00ae (daunorubicin and cytarabine) Prescribing Information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209401s011lbl.pdf\u3009. (Accessed October 11 2022)."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.103984_bib31","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103984_bib32","first-page":"604","article-title":"Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia","volume":"17","author":"Kasner","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103984_bib33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-142891","article-title":"Treatment with CPX-351 induces deep responses and TP53 mutation clearance in patients with t-aml and aml mrc, including younger patients and those with pre-existing MPNs: a real-world experience","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103984_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2022.2092855","article-title":"Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine\/daunorubicin with and without the addition of cladribine","author":"Klingler","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103984_bib36","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103984_bib37","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.103984_bib38","doi-asserted-by":"crossref","unstructured":"LeBlanc, T.W., Morris, S., Hooks, M., Locke, S.C., El-Jawahri, A., 2020. Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial. Poster 2572 presented at American Society of Hematology (ASH) Annual Meeting and Exposition; Virtual, December 5\u20138 2020.","DOI":"10.1182\/blood-2020-139727"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103984_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.clml.2022.06.001","article-title":"CPX-351 yields similar response and survival outcome in younger and older patients with secondary acute myeloid leukemia","volume":"22","author":"Lee","year":"2022","journal-title":"Clin. Lymphoma Myeloma"},{"key":"#cr-split#-10.1016\/j.critrevonc.2023.103984_bib40.1","doi-asserted-by":"crossref","unstructured":"Legg, A., Muzwidzwa, R., Lambova, A., Styles, K., Doubleday, P., Medalla, G., 2022. CPX-351 Treatment for Acute Myeloid Leukemia in England: Real-world Outcomes in Adults Aged <60 Years Versus \u226560 Years. Poster P513 presented at European Hematology Association (EHA) Annual Congress","DOI":"10.1097\/01.HS9.0000844940.77024.41"},{"key":"#cr-split#-10.1016\/j.critrevonc.2023.103984_bib40.2","unstructured":"Vienna, Austria, June 9-12 2022."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103984_bib41","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103984_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2019-124500","article-title":"Genetic characteristics and outcomes by mutation status in a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia (AML)","volume":"134","author":"Lindsley","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-142595","article-title":"Real world outcomes of liposomal daunorubicin and cytarabine versus 7+3 in patients with secondary acute myeloid leukemia","volume":"136","author":"Madarang","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2023.103984_bib45","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103984_bib46","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"Miesner","year":"2010","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib47","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2021-153028","article-title":"CPX-351 induction in secondary acute myeloblastic leukemia: extended follow up from the italian compassionate use program","volume":"138","author":"Minetto","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib48","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2021-150199","article-title":"CPX-351 for acute myeloid leukaemia: real world results are comparable to trial outcomes and exceeds them in non-adverse risk patients - a multicentre experience from West Midlands hospitals on behalf of West Midlands Research Consortium (WMRC) UK","volume":"138","author":"Murthy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103984_bib49","unstructured":"Network, N.C.C., 2022. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline\u00ae): Acute Myeloid Leukemia. Version 2.2022. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf\u3009. (Accessed October 11 2022)."},{"key":"10.1016\/j.critrevonc.2023.103984_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106673","article-title":"Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry","volume":"111","author":"Plesa","year":"2021","journal-title":"Leuk. Res."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib51","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood-2021-153791","article-title":"Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: an updated analysis","volume":"138","author":"Przespolewski","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103984_bib52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103984_bib53","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103984_bib54","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103984_bib55","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103984_bib56","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.103984_bib57","unstructured":"Surveillance Epidemiology and End Results Program, 2019. Cancer Stat Facts \u2014 Acute Myeloid Leukemia (AML). \u3008http:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u3009. (Accessed October 28 2022)."},{"key":"10.1016\/j.critrevonc.2023.103984_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106367","article-title":"Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy","volume":"93","author":"Talati","year":"2020","journal-title":"Leuk. Res."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.103984_bib59","first-page":"51","article-title":"BSH22-PO10: single-centre experience of liposomal daunorubicin and cytarabine (CPX-351) for the treatment of poor risk AML","volume":"197","author":"Taylor","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.103984_bib60","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","article-title":"Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and\/or secondary AML","volume":"6","author":"Uy","year":"2022","journal-title":"Blood Adv."},{"issue":"13","key":"10.1016\/j.critrevonc.2023.103984_bib61","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","article-title":"Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:48:15Z","timestamp":1760903295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":63,"alternative-id":["S1040842823000720"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103984","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with CPX-351 in high-risk acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103984"}}